Suggested remit: To appraise the clinical and cost effectiveness of nintedanib within its marketing authorisation for treating interstitial lung disease caused by systemic sclerosis.
Status In progress
Process STA 2018
ID number 1420

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
20 June 2019 In progress. As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of nintedanib for treating systemic sclerosis associated with interstitial lung disease. Please note that following on from advice received from the company, information regarding the timelines for this appraisal will be available in due course.
11 January 2019 (14:30) Scoping workshop (London)
15 November 2018 - 13 December 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance